Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Christopher P Cannon; Hayes M Dansky; Michael Davidson; Antonio M Gotto; Eliot A Brinton; A Lawrence Gould; Michael Stepanavage; Sherry Xueyu Liu; Sukrut Shah; Joseph Rubino; Patrice Gibbons; Anne Hermanowski-Vosatka; Bruce Binkowitz; Yale Mitchel; Philip Barter

doi:10.1016/j.ahj.2009.07.028

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Christopher P Cannon
, Hayes M Dansky
, Michael Davidson
, Antonio M Gotto
, Eliot A Brinton
, A Lawrence Gould
, Michael Stepanavage
, Sherry Xueyu Liu
, Sukrut Shah
, Joseph Rubino
, Patrice Gibbons
, Anne Hermanowski-Vosatka
, Bruce Binkowitz
, Yale Mitchel
, Philip Barter

Research output: Contribution to journal › Original Article › peer-review

75 Citations (Web of Science)

Original language	English
Pages (from-to)	519.e3
Journal	AMERICAN HEART JOURNAL
Volume	158
Issue number	4
DOIs	https://doi.org/10.1016/j.ahj.2009.07.028
Publication status	Published - 2009

Keywords

HIGH-DENSITY-LIPOPROTEIN
ESTER TRANSFER PROTEIN
CHOLESTEROL LEVELS
THERAPEUTIC TARGET
HDL CHOLESTEROL
TORCETRAPIB
ATHEROSCLEROSIS
ATORVASTATIN
STATINS
SAFETY

Access to Document

10.1016/j.ahj.2009.07.028

Cite this

Cannon, C. P., Dansky, H. M., Davidson, M., Gotto, A. M., Brinton, E. A., Gould, A. L., Stepanavage, M., Liu, S. X., Shah, S., Rubino, J., Gibbons, P., Hermanowski-Vosatka, A., Binkowitz, B., Mitchel, Y., & Barter, P. (2009). Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. AMERICAN HEART JOURNAL, 158(4), 519.e3. https://doi.org/10.1016/j.ahj.2009.07.028

@article{68b2c3399989444783d00708f3812242,

title = "Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.",

keywords = "HIGH-DENSITY-LIPOPROTEIN, ESTER TRANSFER PROTEIN, CHOLESTEROL LEVELS, THERAPEUTIC TARGET, HDL CHOLESTEROL, TORCETRAPIB, ATHEROSCLEROSIS, ATORVASTATIN, STATINS, SAFETY",

author = "Cannon, \{Christopher P\} and Dansky, \{Hayes M\} and Michael Davidson and Gotto, \{Antonio M\} and Brinton, \{Eliot A\} and Gould, \{A Lawrence\} and Michael Stepanavage and Liu, \{Sherry Xueyu\} and Sukrut Shah and Joseph Rubino and Patrice Gibbons and Anne Hermanowski-Vosatka and Bruce Binkowitz and Yale Mitchel and Philip Barter",

year = "2009",

doi = "10.1016/j.ahj.2009.07.028",

language = "English",

volume = "158",

pages = "519.e3",

journal = "AMERICAN HEART JOURNAL",

issn = "0002-8703",

publisher = "Mosby-Year Book Europe",

number = "4",

}

Cannon, CP, Dansky, HM, Davidson, M, Gotto, AM, Brinton, EA, Gould, AL, Stepanavage, M, Liu, SX, Shah, S, Rubino, J, Gibbons, P, Hermanowski-Vosatka, A, Binkowitz, B, Mitchel, Y & Barter, P 2009, 'Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.', AMERICAN HEART JOURNAL, vol. 158, no. 4, pp. 519.e3. https://doi.org/10.1016/j.ahj.2009.07.028

TY - JOUR

T1 - Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

AU - Cannon, Christopher P

AU - Dansky, Hayes M

AU - Davidson, Michael

AU - Gotto, Antonio M

AU - Brinton, Eliot A

AU - Gould, A Lawrence

AU - Stepanavage, Michael

AU - Liu, Sherry Xueyu

AU - Shah, Sukrut

AU - Rubino, Joseph

AU - Gibbons, Patrice

AU - Hermanowski-Vosatka, Anne

AU - Binkowitz, Bruce

AU - Mitchel, Yale

AU - Barter, Philip

PY - 2009

Y1 - 2009

KW - HIGH-DENSITY-LIPOPROTEIN

KW - ESTER TRANSFER PROTEIN

KW - CHOLESTEROL LEVELS

KW - THERAPEUTIC TARGET

KW - HDL CHOLESTEROL

KW - TORCETRAPIB

KW - ATHEROSCLEROSIS

KW - ATORVASTATIN

KW - STATINS

KW - SAFETY

U2 - 10.1016/j.ahj.2009.07.028

DO - 10.1016/j.ahj.2009.07.028

M3 - Original Article

C2 - 19781408

SN - 0002-8703

VL - 158

SP - 519.e3

JO - AMERICAN HEART JOURNAL

JF - AMERICAN HEART JOURNAL

IS - 4

ER -